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ABSTRACT
The incidence of metabolic syndrome (MetS) increases with age, something which is more noticeable in 
women, particularly perimenopausal women. Weight gain and the development of abdominal obesity are 
considered to be the main cause of increased risk of MetS and cardiometabolic factors in perimenopausal 
women. Increased visceral adipose tissue correlates with elevated insulin resistance, inflammation, hyper- 
tension and hyperlipidaemia in middle-aged women. 
In recent years, particular attention has been drawn to the endocrine role of adipose tissue, mainly vis-
ceral adipose tissue, and the concentrations of adipokines and inflammation markers such as: leptin, 
adiponectin, free fatty acids, adipocyte fatty acid binding protein, C-reactive protein (CRP), and inflamma-
tory cytokines. The development of abdominal obesity is mostly associated with a loss of the protective 
role of oestrogens and a relative increase of circulating androgens. After menopause, the adipose tissue 
serves as the primary source of oestrogen production via aromatisation that converts androstenedione 
and testosterone to oestrone and 17b-oestradiol (E2), respectively. Studies looking at the relation between 
menopause and MetS conducted over the past years have mostly focused on the analysis of such hor-
mone balance parameters as: E2, free oestradiol, oestrone and androgenic indicators: total testosterone, 
free testosterone, sex hormone binding globulin or dehydroepiandrosterone sulfate. In most cases, the 
results of the research indicate a greater importance of androgenic markers in the assessment of MetS 
and cardiometabolic risk factors occurrence in perimenopausal and postmenopausal women. 
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Introduction 
Metabolic Syndrome (MetS) is a co-occurrence of 
risk factors of metabolic origin, favouring the devel-
opment of cardiovascular diseases of atherosclerotic 
and type 2 diabetes origins. In recent years, various 
organisations have been introducing criteria for MetS 
diagnosis. Currently, metabolic syndrome is defined on 
the basis of occurrence of the following: abdominal obe-
sity, hypertension, low HDL-cholesterol levels, elevated 
levels of triglycerides (TG) and hyperglycaemia. Ac-
cording to the International Diabetes Federation (IDF), 
abdominal obesity and two additional criteria are es-
sential for a MetS diagnosis [1]. In 2009, IDF criteria 
were updated and harmonised with the recommen-
dations of other associations and organisations such 
as: the National Heart, Lung and Blood Institute, the 
American Heart Association, the World Health Federa-
tion, the International Atherosclerosis Society and the 
International Association for the Study of Obesity. How-
ever, the most important change was the introduction 
of a choice of three out of five criteria, excluding a need 
for abdominal obesity occurrence when diagnosing 
MetS (Tab. 1) [2]. 
In recent years, a notion of ‘cardiometabolic risk’ 
has arisen. Cardiometabolic risk is defined as the co-oc-
currence of risk factors that increase the risk of cardiac 
diseases and type 2 diabetes. Cardiometabolic risk is 
not a disease but rather a group of disorders, which, 
occurring individually or together, can increase cardiac 
disease and type 2 diabetes risks. The following can 
be listed as cardiometabolic risk factors: abdominal 
obesity, low HDL-C levels, high levels of triglycerides, 
total cholesterol, LDL cholesterol, glucose, increased 
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Table 1. Chosen definitions of MetS
NCEPT: ATPIII1 (2001)
Any three out of the following: 
– waist circumference in men > 102 cm, in women > 88 cm
– plasma TG concentration ≥ 150 mg/dL or HDL-C < 40 mg/dL in men and < 50 mg/dL in women
– arterial pressure ≥ 130/85 mm Hg
– fasting glucose ≥ 110 mg/dL
IDF2 (2005)
Improper waist circumference (depending on population) in European men ≥ 94 cm, in women ≥ 80 cm
Plus two of the following:
– plasma TG concentration ≥ 150 mg/dL or HDL-C < 40 mg/dL in men and < 50 mg/dL in women or hypoglycaemia treatment
– arterial pressure ≥ 130/85 mm Hg or antihypertensive treatment
– fasting glucose ≥ 100 mg/dL or hypoglycaemia treatment
Consensus definition IDF and AHA/NHLBI3 (2009)
Any three of the following: 
– improper waist circumference (depending on population) in European men ≥ 94 cm, in women ≥ 80 cm
– plasma TG concentration ≥ 150 mg/dL or HDL-C<40 mg/dL in men and < 50 mg/dL in women or hypoglycaemia treatment
– arterial pressure ≥ 130/85 mm Hg or antihypertensive treatment
– fasting glucose ≥ 100 mg/dL or hypoglycaemia treatment
1National Cholesterol Education Programme Adult Treatment Panel III; 2International Diabetes Federation; 3American Heart Association/National 
Heart Lung and Blood Institute; TG — triglycerides; HDL-C — high-density lipoprotein-cholesterol
rates of insulin resistance and inflammation, hyperten-
sion, and smoking.
The results of epidemiological research indicate 
a high prevalence of MetS in the USA and in Europe, 
including Poland. It is estimated that 20–25% of the adult 
population of developed countries meet the MetS diag-
nostic criteria [3]. The results of the multi-centre Polish 
Research on Health State of Population programme 
(WOBASZ — Wielkoośrodkowe Ogólnopolskie Badanie 
Stanu Zdrowia Ludności) show that in Poland MetS is 
diagnosed in every fifth person on average (19–23% 
of men and 19–20% of women) [4]. It is estimated that 
individuals with MetS have a two-fold increased risk of 
cardiac disease and a five-fold increased risk of type 2 
diabetes.
The incidence of MetS increases with age, some-
thing which is more noticeable in women, particularly 
perimenopausal women. According to various data, 
the prevalence of MetS during this period increases 
significantly and is estimated to be 31–41% [5–7]. It 
has been proven that in postmenopausal women the 
risk of MetS is increased by up to 60%, not dependent 
on BMI, age or physical activity [8]. 
Weight gain and the development of abdominal 
obesity are considered the main cause of increased 
risk of MetS and cardiometabolic factors in perimeno-
pausal women. Increased visceral adipose tissue cor-
relates with elevated insulin resistance, inflammation, 
hypertension and hyperlipidaemia in middle-aged 
women. In recent years, particular attention has been 
drawn to the endocrine role of adipose tissue, mainly 
visceral adipose tissue. It has been shown that adi-
pose tissue can influence the development of MetS 
by secreting adipokines as well as growth factors and 
cytokines. These compounds participate in a number of 
metabolic processes related to carbohydrate and lipid 
balance, inflammations, coagulation, feelings of hunger 
and satiety in the central nervous system. While setting 
criteria for MetS diagnosis, the International Diabetes 
Federation (IDF) focused on obesity as the main crite-
rion for MetS and supplemented the classification of 
MetS with additional parameters such as: concentration 
of leptin, adiponectin, free fatty acids, CRP, inflamma-
tory cytokines (Il-6, TNF-a), and prothrombotic factors 
(fibrinogen, PAI-1) [9]. These parameters are known as 
‘platinum standards’ due to their significant role in the 
development of MetS [10]. 
Relation of CRP, adiponectin, leptin and 
A-FABP to MetS and cardiometabolic 
risk factors incidence in women
CRP
Low-intensity inflammation is an important factor in 
subjects with MetS and can contribute to an increased 
risk of cardiovascular diseases and the development 
of diabetes. Among various studied inflammatory 
biomarkers, CRP is the best documented and most 
standardised parameter. Numerous studies have 
confirmed a relation between CRP and MetS and 
cardiometabolic risk factors [10–12]. A strong correla-
tion between CRP and MetS factors, LDL, insulin and 
HOMA-1 level has been demonstrated. Ridker et al. 
in their eight-year prospective study (Women Health 
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Study) found that CRP above 3 mg/L in MetS women 
is related to a higher relative risk (RR) of cardiovascu-
lar disorders [13]. Studies using recombinant human 
CRP have demonstrated that CRP can directly inter-
fere with the insulin signalling pathway and stimulate 
inflammation in the vascular endothelium by increas-
ing the expression of adhesion molecules [14, 15]. 
Furthermore, it has been observed that leptin cor-
related positively with CRP in MetS subjects, while the 
correlation of adiponectin with CRP was negative [16]. 
It is worth mentioning that CRP is a sensitive but 
non-specific inflammatory biomarker, which makes its 
contribution in the assessment of cardiometabolic risk 
difficult to quantify. 
Adiponectin 
Adiponectin is a polypeptide hormone that is pro-
duced and secreted into the blood by mature adipo-
cytes. Adiponectin level in the blood is relatively high 
compared to other hormones and constitutes 0.01% of 
all plasma proteins. Furthermore, adiponectin concen-
tration is higher in women than in men and increases 
with age. Also, higher levels of adiponectin are observed 
in postmenopausal women compared to premeno-
pausal women. Reduced adiponectin level is related 
to obesity, MetS, type 2 diabetes and cardio-vascular 
disorders. Adiponectin influences a number of meta-
bolic processes, particularly glucose and fatty acid me-
tabolism in the liver and muscles. Therefore, it presents 
anti-inflammatory, antiatherosclerotic and insulin-sen-
sitising activity. A lower adiponectin concentration is 
also considered to be a link between visceral obesity 
and insulin resistance [17]. The latest studies suggest 
that adiponectin improves insulin sensitivity better in 
postmenopausal than in premenopausal women [18].
Leptin 
Leptin is a hormone secreted by adipocytes which 
is involved in the regulation of food intake and ener-
gy balance. After binding leptin to receptors in the 
hypothalamus, neurons cease to produce neuropep-
tide Y — an appetite stimulant. By these means, the 
hormone suppresses the appetite and stimulates the 
sympathetic system. Leptin concentration correlates 
positively with the amount of body fat and is higher in 
women than in men [19]. However, no difference was 
found among groups of premenopausal and postmeno-
pausal women. In women, leptin is secreted mainly by 
subcutaneous adipose tissue [20]. Disorders of leptin 
secretion as well as lack of receptors’ sensitivity for 
this hormone often lead to excess weight or obesity. 
In the majority of cases, obesity is accompanied by 
hyperleptinaemia; it seems that obese people become 
insensitive to the effects of endogenous leptin. Numer-
ous studies have proved the participation of leptin in 
the development of insulin resistance, hypertension or 
hyperleptinaemia [21].
Adipocyte fatty acid binding protein (A-FABP) 
— a new adipokine related to pathophysiology, 
MetS occurrence and cardiometabolic risk factors 
A-FABP belongs to the fatty acid binding pro-
teins. Mostly it is synthesised and released by 
subcutaneous adipocytes. In adipocytes, it con-
stitutes almost 1% of the total cytosol protein, 
while, to a smaller extent, it is produced in macro-
phages and endothelial cells. Cytoplasmic A-FABP 
binds mainly long chained fatty acids, then directs 
them to appropriate intracellular disposal [22]. 
A-FABP participates in the pathophysiology of MetS, 
particularly by inducing hypertriglyceridaemia and in-
sulin resistance. Studies in animals have demonstrated 
that A-FABP deletion protected obese mice from insulin 
resistance, hyperinsulinaemia and increased glucose 
concentration [23]. Moreover, A-FABP participates in 
the development of atherosclerotic lesions by promot-
ing the accumulation of triglycerides and cholesterol in 
macrophages and inducing proinflammatory cytokines 
in macrophages. A-FABP’s influence on endothelial cell 
proliferation and angiogenesis has also been suggest-
ed. In recent years, A-FABP has been recognised as 
a biomarker of MetS, type 2 diabetes and cardiovascular 
disorders [24]. It has been also demonstrated that se-
rum A-FABP concentration is higher in women than in 
men, similarly to the relation of A-FABP and cardiomet-
abolic risk factors. It is suggested that this difference 
is due to women’s greater content of subcutaneous 
adipose tissue.
Relation of sex hormones to MetS, type 
2 diabetes and cardiometabolic risk 
factors incidence in women
The development of abdominal obesity, and thereby 
higher incidence of MetS or type 2 diabetes in perimeno-
pausal and postmenopausal women, is mostly asso-
ciated with a loss of the protective role of oestrogens 
and a relative increase of circulating androgens. After 
the menopause, when ovarian production ceases and 
ovarian feedback is lost, the adipose tissue serves as 
the primary source of oestrogen production via aroma-
tisation that converts androstenedione and testosterone 
to oestrone (E1) and E2, respectively. Therefore, obese 
postmenopausal women have higher concentrations of 
E2, E1 and oestrone sulfate than non-obese postmeno-
pausal women [25, 26]. Studies looking at the relation 
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between menopause and MetS conducted over recent 
years have mostly focused on the analysis of such 
hormone balance parameters as: 17b-oestradiol, 
free oestradiol, oestrone and androgenic indicators: 
total testosterone, free testosterone, sex hormone 
binding globulin (SHBG) or dehydroepiandrosterone 
sulfate (DHEA-S). In most cases, the results of the 
research indicate a greater importance of androgenic 
markers (especially testosterone and SHBG) in the 
assessment of MetS and cardiometabolic risk factors 
occurrence in perimenopausal and postmenopausal 
women [27, 28]. 
Sex hormone binding globulin (SHBG)
Sex hormone binding globulin (SHBG) is a protein 
synthesised in the liver that transports sex hormones 
into the blood. Since SHBG has a higher affinity to 
testosterone binding than oestradiol binding, it is con-
sidered an efficient androgenisation biomarker [29]. 
Assessing total testosterone concentration including 
SHBG allows a calculation of the amount of bioavailable 
testosterone and free androgen index.
In women, oestrogens stimulate SHBG synthesis, 
whereas androgens, insulin and excess weight, partic-
ularly visceral obesity, influence a decrease of SHBG 
synthesis. It has been demonstrated that the positive 
effect of oestrogens on SHBG synthesis is stronger 
in premenopausal than in postmenopausal women. 
A number of studies indicate that insulin is a potent 
inhibitor of SHBG synthesis; therefore, this protein 
is considered a good indicator of insulin resistance. 
Reduced SHBG concentration is observed as an effect 
of severe androgenisation and hyperinsulinaemia in 
women with polycystic ovary syndrome (PCOS) and 
in obese postmenopausal women [30, 31]. A relation 
has also been demonstrated in women between re-
duced SHBG concentration and MetS incidence, type 2 
diabetes and cardiovascular disorders. Low plasma 
concentration of SHBG is weakly associated with type 2 
diabetes in men [32]. 
Testosterone
Testosterone is a steroid hormone, which is secreted 
primarily by the testicles of males and the ovaries of 
females, although small amounts are also secreted by 
the adrenal glands. In postmenopausal women without 
diabetes, endogenous total and free testosterone con-
centration is positively associated with markers of in-
sulin resistance and measures of adiposity [33–35]. On 
the contrary, testosterone is inversely associated with 
adiposity in men. Experiments in female rats showed 
that testosterone impairs insulin-mediated glucose 
uptake and increases lipogenesis [36]. The results of 
cross-sectional studies have shown that middle-aged 
women with type 2 diabetes had significantly higher 
levels of testosterone compared to controls, whereas 
men with type 2 diabetes had significantly lower plasma 
total testosterone. These sex-dependent differences 
remained significant even after adjusting for study-level 
differences in age, race and diabetes diagnosis criteria, 
as well as internal control for BMI and WHR. Several 
potential explanations exist for the elevations in an-
drogen levels in postmenopausal diabetic women. It is 
possible that the reduction in SHBG concentration in 
diabetic women permits more testosterone to circulate 
in its unbound or active form. Moreover, the ovaries of 
postmenopausal women remain hormonally active, 
with an increase in the ratio of androgen to oestrogen 
production [37]. 
Dehydroepiandrosterone sulfate 
Dehydroepiandrosterone (DHEA) is a steroid 
hormone produced in the adrenal cortex from 
cholesterol. It is the primary precursor of natu-
ral oestrogens. Dehydroepiandrosterone sulfate 
(DHEAS) is a more stable circulating form of this 
hormone. Endogenous DHEAS has been positively 
associated with both insulin resistance and cen-
tral adiposity in postmenopausal women [38, 39]. 
However, other studies have suggested that DHEAS 
is inversely associated with diabetes and insulin re-
sistance, or is not associated with insulin resistance 
and other components of metabolic syndrome [40]. 
Human investigations of exogenous DHEA and glucose 
metabolism have yielded controversial results [41, 42]. 
Some authors have found that treatment with DHEA 
decreased visceral adiposity and improved insulin 
action, while others did not observe any benefits of 
DHEA [43, 44]. 
Oestradiol
The results examining an association between 
oestradiol (E2) concentration and the parameters of 
metabolic syndrome and type 2 diabetes are diver-
gent. Although some studies have shown a positive 
correlation between oestradiol and insulin resistance 
or type 2 diabetes in postmenopausal women, even 
after controlling for BMI [45, 46], other studies have 
shown no such relationship [47]. The relationship 
between elevated oestradiol concentration and met-
abolic syndrome parameters is mainly explained by 
the fact that E2 concentration is a marker of increased 
aromatase conversion of androgens in adipocytes of 
postmenopausal women. The free E2 is a better mark-
er of metabolic disturbances because this fraction is 
more biologically active and is associated with a lower 
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level of SHBG in women. E2 may be associated with 
diabetes risk through its relation to insulin resistance, 
adiposity, and/or inflammatory markers. High endog-
enous E2 in physiological states such as puberty, the 
luteal phase of the menstrual cycle, and late pregnan-
cy, are associated with insulin resistance and may in-
volve reduced glucose transporter 4 (GLUT4) muscle 
expression [48]. Although studies of low-dose exoge-
nous E2 in the form of hormone replacement therapy 
have been associated with a lower risk of diabetes in 
postmenopausal women, other studies have found 
exogenous oral E2 administration at higher doses 
to be associated with greater insulin resistance [46]. 
Endogenous E2 is also associated with the develop-
ment of adiposity [35, 49], although endogenous E2, 
itself, results from aromatisation of androgens in 
adipocytes; thus, the relationship between E2 and 
adiposity is likely to be bidirectional. One animal 
study suggested that E2 may have direct effects on 
adipocyte enlargement, and in consequence, weight 
gain [50], although other studies show the opposite 
effect [51, 52]. E2 may also have effects on diabetes 
incidence through its association with inflammatory 
markers. Elevated inflammatory factors such as 
CRP have been found in women on oral oestrogen 
treatment [53], and inflammatory markers have also 
been positively associated with endogenous oestrone 
levels [54]. Because inflammatory markers have been 
linked to the development of diabetes [55], this might 
provide another mechanism by which E2 could lead to 
diabetes. E2 is also associated with lipid abnormalities 
and lower physical activity [56]. 
Follicle-stimulating hormone
Follicle-stimulating hormone (FSH) is a glycoprotein 
secreted by the anterior pituitary gland. In men, FSH 
stimulates the seminiferous epithelium and synthesis of 
testosterone, while in the follicular phase in premeno-
pausal women it stimulates follicular development and 
initiates oestrogen synthesis; in the luteal phase, it 
stimulates the production of progesterone. Secretion 
of FSH is regulated by oestradiol and testosterone 
affecting hypothalamus by a negative feedback. In the 
early stage of the postmenopausal period, FSH level 
is changeable; however, in the late stage it increases 
(above 25 IU/L). The highest FSH concentration can 
be observed 2–3 years after menopause when oes-
trogen production is reduced and hormone balance 
is set at a new level with low oestrogen concentration 
and high gonadotropin concentration. According to 
the latest recommendations [Stages of Reproductive 
Ageing Workshop (STRAW) + 10], the level of FSH 
and oestradiol (E2) is stabilised about two years after 
the last menstruation [57, 58]. FSH measurement 
is used mostly in infertility and impotence diagnos-
tics, as well as in menstrual and maturation disor-
ders. The association between FSH and MetS factors 
is described mostly in premenopausal PCOS women 
and men with type 2 diabetes. PCOS is related to 
weight excess and visceral obesity as well as the 
development of insulin resistance. The probability 
of type 2 diabetes occurrence is 5-10-fold higher 
in PCOS women compared to healthy women. In 
PCOS women, a higher LH concentration and an 
unchanged/decreased FSH level can be observed. In 
PCOS diagnostics, LH/FSH evaluation (value up to 2.5) 
is used [59, 60]. Reduced LH and FSH along with low 
free testosterone level (hypogonadotropic hypogo-
nadism) can be observed in 25% of men with type 2 
diabetes. Hypogonadotropic hypogonadism in men 
is related to visceral obesity, insulin resistance, MetS 
and increased CRP [61]. After menopause, a negative 
correlation between the concentration of FSH and BMI 
has also been observed [62, 63]. 
Conclusion 
The incidence of MetS or type 2 diabetes increases 
with age, something which is more noticeable in wom-
en, particularly perimenopausal women. Recent studies 
have clearly shown that the development of metabolic 
disorders is significantly associated with concentrations 
in the circulation of adipokines and sex hormones in 
women during menopausal transition. 
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